Sandwich type kit for detecting cardiovascular disease markers and preparation method thereof
By combining pentapeptide carrier material with artificial antibodies, a sandwich kit is prepared, which solves the problem of insufficient complexity and sensitivity of cardiovascular disease detection methods, and realizes rapid detection of portable, low-cost, multiple markers, suitable for heart failure and diagnosis of myocardial infarction.
Patent Information
- Application Number
- CN202411229835.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-11-29
AI Technical Summary
The existing cardiovascular disease detection methods have problems such as complex and expensive equipment, difficult operation, and susceptible to pollution and environmental factors. Especially in the early diagnosis of acute myocardial infarction, the sensitivity and specificity of the traditional methods are insufficient and cannot be Effectively identify multi-cardiovascular disease markers.
Using pentapeptide (Cys-Glu-Cys-Gly-Cys) as the link bridge between artificial antibodies I and II, through fluorescently modified artificial antibodies II binding to target markers, quantitative determination was performed using fluorescent signals to prepare a sandwich Kits for identification of cardiovascular disease markers such as NT-proBNP, BNP, Myo, CK-MB, cTnT or cTnI.
Achieve portable, reliable, highly sensitive, low-cost and fast cardiovascular disease marker detection, overcome the equipment complexity and single-index detection limitations of traditional methods, and provide a low-cost, high-stability multi-marker detection The protocol is suitable for the diagnosis of heart failure and myocardial infarction.
Smart Images

Figure CN119044507A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the field of biomedical technology, and in particular relates to a sandwich kit for detecting cardiovascular disease markers and a preparation method thereof. Background Art
[0002] Cardiovascular disease is one of the leading causes of death worldwide, causing more than 17.3 million deaths each year, and this number is expected to exceed 23.6 million by 2030. Among various cardiovascular diseases, myocardial infarction is particularly dangerous, especially in the absence of effective early diagnosis methods, and its high mortality rate is worrying. Acute myocardial infarction is one of the most common cardiovascular diseases in clinical practice, and its early diagnosis is crucial. Traditional methods for detecting acute myocardial infarction mainly include electrocardiogram, chest X-ray and echocardiography. However, the latest studies have shown that these methods are not always reliable and may sometimes fail in 70% of cases. Serological diagnosis is of great significance in the diagnosis of myocardial infarction due to its sensitivity and specificity. The most specific markers of myocardial infarction are troponin I (cTnI) and troponin T (cTnT), which are very specific indicators for diagnosing myocardial infarction. Taking cTnT as an example, the normal value of cTnT in the body is generally 0.02-0.13 μg / L. If it is greater than 0.2 μg / L, it indicates possible myocardial strain, and if it is greater than 0.5 μg / L, it may be an acute myocardial infarction. cTnT often begins to rise 3-4 hours after onset, reaches a peak at 24-48 hours, and can return to normal levels in 10-14 days.
[0003] Statistics show that almost all cardiovascular diseases will eventually lead to heart failure. Myocardial damage caused by any reason, such as myocardial infarction, cardiomyopathy, hemodynamic overload, inflammation, etc., will cause changes in myocardial structure and function, and ultimately lead to a decrease in ventricular pumping and / or filling function. Cardiac biomarker analysis of patient blood samples is currently introduced as a standard method for detecting heart failure. For example, N-terminal pro-B-type natriuretic peptide (NT-proBNP) is an effective predictor of death and heart failure in a variety of populations. After a high-risk myocardial infarction, NT-proBNP levels within the first week are considered a predictor of cardiovascular death or heart failure. An increase in NT-proBNP means that it is associated with a greater risk of heart failure events and death after myocardial infarction. Generally speaking, acute heart failure is diagnosed based on clinical manifestations plus NT-proBNP>300 ng / L; patients with acute exacerbation of chronic heart failure are divided according to manifestations and age: patients under 50 years old have NT-proBNP>450 ng / L, those over 50 years old have NT-proBNP>900 ng / L, those over 75 years old have NT-proBNP>1800 ng / L, and those with renal insufficiency (glomerular filtration rate <60mL / min) have NT-proBNP>1200ng / L to diagnose heart failure. In addition to NT-proBNP, brain natriuretic peptide (BNP), myoglobin (Myo), creatine kinase isoenzyme (CK-MB), etc. are also often used to diagnose heart failure, predict patient prognosis, monitor treatment effects, and prevent the occurrence of acute dyspnea originating from the heart. The concentrations of these markers in the blood of healthy people are extremely low.
[0004] At present, electrochemiluminescence detection has been widely used in clinical practice due to its high sensitivity, low background signal and good controllability. However, the detection equipment required for this method is complex and expensive, and the initial investment is high. In addition, operation and maintenance require professional technicians, which increases the difficulty of operation. Another issue that needs attention is that the electrode surface is susceptible to contamination, which may affect the accuracy of the test results. Chemiluminescence is another common detection method in clinical practice. In contrast, the detection equipment required for this method is relatively simple and low in cost. However, the chemiluminescence reaction is easily affected by environmental factors and may produce a high background signal, which in turn affects the accuracy of the test results. In addition, the chemiluminescence method can usually only detect a single indicator, and cannot achieve the detection of multiple indicators like the electrochemiluminescence detection method.
[0005] Artificial antibodies, also known as synthetic antibodies, are antibodies designed and manufactured by biological or chemical techniques, and have functions similar to natural antibodies. Antibodies synthesized by chemical techniques include several important processes. First, the main functional monomers of synthetic antibodies are determined by computer or coarse-grained simulation, which are generally some vinyl compounds containing double bonds. These compounds have different types of functional groups, such as -COOH, -NH2, -SH and strong hydrophobic groups, which establish the basis for molecular recognition. Subsequently, the best synthetic antibodies targeting antigens are determined by methods such as molecular imprinting or high-throughput screening. The artificial antibodies thus obtained can accurately recognize and bind to specific antigens, improving the accuracy of diagnosis and treatment. In this case, artificial antibodies can quantify the presence of biomarkers as specific biomarker recognition devices. Compared with biological antibodies, artificial antibodies also have many advantages, namely, they can resist environmental changes and have high physicochemical stability in various solvents, pH values or temperatures. These characteristics provide them with the potential to compete as a real alternative to immunoassays and can be used to effectively identify organic small molecules, macromolecules, proteins or viruses. Summary of the invention
[0006] The present invention aims to provide a sandwich kit for detecting cardiovascular disease markers and a preparation method thereof. The present invention selects two epitope polypeptides at different positions of the target marker as targets and corresponding artificial antibodies I and II that can specifically recognize the two epitope polypeptides. A pentapeptide (Cys-Glu-Cys-Gly-Cys) similar to the structure of glutathione is used as a "linking bridge" between the carrier material and the artificial antibody I, and the artificial antibody I containing a primary amino group is modified onto the carrier material, and then used to adsorb the marker in the detection sample, and then the fluorescently modified artificial antibody II is used to bind to the target marker adsorbed on the carrier material, and the content of the target marker in the sample is quantitatively determined by detecting the fluorescent signal.
[0007] The sandwich kit for detecting cardiovascular disease markers consists of an artificial antibody II and an artificial antibody I modified on a carrier material.
[0008] The carrier material is amino-modified glass or a magnetic material with amino functional groups.
[0009] The modification method of the amino-modified glass is as follows: treating the glass with acid, alkali and ethanol solution in sequence to activate the hydroxyl groups; then adding 1-20wt% APTMS ethanol solution, 25-40 o C for 6-24h, and finally rinse with ultrapure water.
[0010] The acid treatment uses a 0.5-5 M hydrochloric acid solution, the alkali treatment uses a 0.5-5 M sodium hydroxide solution, and the ethanol solution is an ethanol aqueous solution with a volume content of 50-95%.
[0011] The cardiovascular disease marker is NT-proBNP, BNP, Myo, CK-MB, cTnT or cTnI.
[0012] The preparation method of the artificial antibody I is: preparing a mixed monomer solution with a concentration of 13-65 mM, wherein the mixed monomer is a molar ratio of 45-98:5-45:5-45:1-10:1-5 N -isopropylacrylamide (NIPAm), N - tert-butyl acrylamide (TBAm), N -phenylacrylamide (PAm), N -(3-aminopropyl)methacrylamide (APM) and N,N' -methylenebisacrylamide (Bis), then sodium dodecyl sulfate (SDS) is added, the amount of sodium dodecyl sulfate added is 0.02-0.2 mg / mL, ultrasonic nitrogen is passed through for 5-30 min to remove oxygen from the solution, and then ammonium persulfate (APS) is added to initiate the polymerization reaction, the amount of ammonium persulfate added is 0.6-1.2 mg / mL, and the polymer nanoparticles synthesized are artificial antibody I.
[0013] The preparation method of the artificial antibody II is as follows: preparing a mixed monomer solution with a concentration of 13-65 mM, wherein the mixed monomers are N-isopropylacrylamide (NIPAm), N-tert-butylacrylamide (TBAm), N-phenylacrylamide (PAm), acrylic acid (AAc) and N,N'-methylenebisacrylamide (Bis) in a molar ratio of 45-98:5-45:5-10:1-10:1-5, then adding sodium dodecyl sulfate (SDS) in an amount of 0.02-0.2 mg / mL, ultrasonically passing nitrogen for 5-30 minutes to remove oxygen in the solution, then adding fluorescein in an amount of 0.04-0.1 mg / mL, and finally adding ammonium persulfate (APS) to initiate a polymerization reaction, wherein the amount of ammonium persulfate added is 0.6-1.2 mg / mL, and synthesizing fluorescently labeled polymer nanoparticles, namely artificial antibody II.
[0014] The method for modifying the artificial antibody I on the carrier material is as follows: first, the carrier material is added to a 0.5-2 mg / mL sulfo-SMCC solution for reaction at room temperature for 20-50 min, and then the carrier material is taken out and rinsed with deionized water; then, the carrier material is added to a 1-5 mg / mL Cys-Glu-Cys-Gly-Cys pentapeptide solution for reaction at room temperature for 20-50 min, and then the carrier material is taken out and rinsed with deionized water; then, the carrier material is added to a 0.5-2 mg / mL sulfo-SMCC solution for reaction at room temperature for 20-50 min, and then the carrier material is taken out and rinsed with deionized water; finally, a phosphate buffer solution of artificial antibody I with a concentration of 0.05-1 mg / mL is added, and then the carrier material is rinsed with deionized water for 35-50 min. o C for 10-30h and washed with ultrapure water.
[0015] The method of using the sandwich kit for detecting cardiovascular disease markers is as follows: adding the test sample to the carrier material modified with artificial antibody I for adsorption reaction at room temperature for 5-10 minutes, and rinsing with deionized water; then adding artificial antibody II solution, reacting at room temperature for 5-10 minutes, and rinsing with deionized water; finally, quantitatively determining the content of cardiovascular disease markers in the test sample by detecting fluorescence signals.
[0016] The present invention has the following beneficial effects: (1) The present invention uses pentapeptide (Cys-Glu-Cys-Gly-Cys) as a coupling agent, avoiding nonspecific adsorption caused by the introduction of secondary structures by ultra-long peptide chains, and the pentapeptide has good hydrophilicity and biocompatibility, thereby reducing the interference of serum albumin on detection. The pentapeptide has a cysteine at both ends and in the middle, which can not only meet the coupling requirements of artificial antibodies and substrate materials, but also increase the modification amount of artificial antibodies in the substrate materials. The artificial antibodies and substrate materials are linked by the thiol functional groups in the pentapeptide, and the reaction conditions are mild and the operation is simple and easy to complete, which are not possible with chemical coupling reagents.
[0017] (2) The particle size of the artificial antibody prepared by the present invention is 5-500 nm, the potential is between -39.6 mV and 24.5 mV, and the binding to the target is K D Values up to 10 -12 M, with high affinity and good selectivity, can replace protein antibodies, identify NT-proBNP, NT-proBNP, BNP, Myo, CK-MB, and cTnT or cTnI, and is used for the diagnosis of cardiovascular diseases, especially heart failure and myocardial infarction. The artificial antibody is prepared by chemical methods, with low cost, high stability, long service life and strong resistance to harsh environments, overcoming the shortcomings of monoclonal protein antibodies such as long preparation cycle, instability, easy inactivation and high cost.
[0018] (3) The present invention uses chemically synthesized artificial antibodies as recognition elements to prepare a sandwich kit for the quantitative detection of cardiac markers. The detection time of the kit can be controlled within 13 minutes, while the detection time of electrochemiluminescence and chemiluminescence methods is 15-75 minutes. The detection limit LOD of the kit is 2.52-11.91 pg / mL (for example, the LOD of NT-proBNP is 2.52 pg / mL), which is better than the LOD of electrochemiluminescence and chemiluminescence methods commonly used in clinical practice (4-10 pg / mL), providing a portable, reliable, highly sensitive, low-cost, accurate and rapid method for the detection of cardiovascular disease markers. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Scanning electron microscopy (SEM) images of artificial antibodies I (upper left) and II (upper right) targeting NT-proBNP and artificial antibodies I (lower left) and II (lower right) targeting cTnT synthesized in Example 1.
[0020] Figure 2 From left to right are the Zeta potential diagrams of artificial antibodies I and II targeting NT-proBNP and artificial antibodies I and II targeting cTnT synthesized in Example 1.
[0021] Figure 3 In Example 2, the quartz glass pores were modified with fluorescent artificial antibodies.
[0022] Figure 4 The fluorescence intensity of the modified fluorescent artificial antibodies in each well on different quartz glass plates in Example 2.
[0023] Figure 5 Example 3 Detection regression curve of the artificial antibody kit (upper left), relative standard deviation (RSD) of artificial antibodies from the same batch (upper right); relative standard deviation (RSD) of artificial antibodies from different batches (lower left), and detection results of actual serum samples (lower right).
[0024] Figure 6 Example 4 Detection regression curve of the artificial antibody kit (upper left), relative standard deviation (RSD) of artificial antibodies from the same batch (upper right); relative standard deviation (RSD) of artificial antibodies from different batches (lower left), and detection results of actual serum samples (lower right).
[0025] Figure 7 Example 5 Detection correlation curve of the immunomagnetic bead kit. DETAILED DESCRIPTION
[0026] Example 1: Synthesis of artificial antibodies 1. Synthesis of artificial antibodies targeting NT-proBNP
[0027] Artificial antibody I includes 83% NIPAm, 5% TBAm, 10% APM, 2% Bis and 0.02 mg / mL mg SDS, and artificial antibody II includes 45% NIPAm, 40% PAm, 10% AAc, 5% Bis and 0.02 mg / mL SDS (each percentage is the percentage of the molar number of each monomer to the total molar number of monomers). The monomers NIPAm, APM, AAc, Bis and SDS are each dissolved in 1 mL of water, and TBAm and PAm are each dissolved in 1 mL of ethanol. After adding the monomer mixture of each polymer to a 100 mL single-necked flask, adjust the final volume to 50 mL with water. After sealing, ultrasonic nitrogen gas is passed for 30 min. Among them, the total monomer concentration of artificial antibody I is 13 mM, and the reaction is carried out directly. The total monomer concentration of artificial antibody II is 13 mM, and 0.04 mg / mL FAM (1 mL ethanol solution) needs to be added to the reaction system, and the entire reaction needs to be protected from light. 0.6 mg / mL APS was added to both artificial antibody I and artificial antibody II as an initiator, and the reaction was carried out at 65°C for 3 hours. After the reaction, the obtained nanoparticle solution was transferred to a dialysis bag (molecular weight cutoff time: 14000 Da) and dialyzed for 3 days. Finally, the obtained artificial antibody solution was stored in a 50 mL centrifuge tube for later use. 2. Synthesis of artificial antibodies targeting cTnT
[0028] Artificial antibody I includes 49% NIPAm, 45% TBAm, 1% APM, 5% Bis and 0.2 mg / mL SDS, and artificial antibody II includes 89% NIPAm, 5% PAm, 5% AAc, 1% Bis and 0.1 mg / mL SDS. The monomers NIPAm, APM, AAc, Bis and SDS are each dissolved in 1 mL of water, and TBAm and PAm are each dissolved in 1 mL of ethanol. After adding the monomer mixture of each polymer to a 100 mL single-necked flask, the final volume is adjusted to 50 mL with water. After sealing, ultrasonic nitrogen is passed for 30 minutes. Among them, the total monomer concentration of artificial antibody I is 65 mM, and the reaction is carried out directly. The total monomer concentration of artificial antibody II is 65 mM, and 0.1 mg / mL FAM (1 mL ethanol solution) needs to be added to the reaction system, and the entire reaction needs to be protected from light. 1.2 mg / mL APS is added to both artificial antibody I and artificial antibody II as an initiator, and the reaction is carried out at 65°C for 3h. After the reaction, the obtained nanoparticle solution was transferred to a dialysis bag (molecular weight cutoff: 14000 Da) and dialyzed for 3 days. Finally, the obtained artificial antibody solution was stored in a 50 mL centrifuge tube for later use.
[0029] Figure 1 Scanning electron micrographs of synthesized artificial antibodies I (upper left) and II (upper right) targeting NT-proBNP and artificial antibodies I (lower left) and II (lower right) targeting cTnT are shown. Figure 2 The zeta potentials of the synthesized artificial antibodies I and II targeting NT-proBNP and the artificial antibodies I and II targeting cTnT are shown, which are 24.5 mV, -39.6 mV, 8.4 mV and -11.9 mV from left to right, respectively. Example 2: Preparation of the kit 1. Activated quartz glass hole
[0030] Prepare 100 mL of 1 M hydrochloric acid solution, soak the quartz glass plate in room temperature ultrasound for 30 min, and rinse it with deionized water; then soak the quartz glass plate in ultrapure water and ultrasound for 10 min; then place the quartz glass plate in 100 mL of 1 M sodium hydroxide solution, ultrasound at room temperature for 30 min, and rinse it with ultrapure water; finally, place the quartz glass plate in 100 mL of ethanol solution (50% v / v), ultrasound at room temperature for 30 min, blow dry with nitrogen, and set aside. 2. Quartz glass pore modification with amino groups
[0031] Add 200 µL of 5% (w / w) APTMS ethanol solution (ethanol solution is 95% v / v, pH 5) to the quartz glass hole and incubate at 40 o C for 12 h, rinse with deionized water and set aside. 3. Quartz glass hole coupling artificial antibody
[0032] After preparing 5 mg / mL of pentapeptide (Cys-Glu-Cys-Gly-Cys) solution and 1 mg / mL of sulfonic acid-SMCC solution with 0.01 M PBS (pH 7.2-7.4), 100 µL of sulfonic acid-SMCC solution was added to the quartz glass well plate and reacted at room temperature for 30 min. Rinse with deionized water 2-3 times. Then, 100 µL of peptide solution was added to each well of the quartz glass well and reacted at room temperature for 30 min. Rinse with deionized water 2-3 times. 100 µL of sulfonic acid-SMCC solution was added again and reacted at room temperature for 30 min. Rinse with deionized water 2-3 times. Finally, 50 µL of amino-containing artificial antibody I solution (concentration 0.1 mg / mL, diluted with PBS, pH=6.8) was added to each well of the quartz glass well and placed at 40 o C in an oven for 12 h.
[0033] To verify whether the above method is effective in modifying artificial antibodies onto quartz glass wells, we synthesized fluorescent nanoparticles. Figure 3 It can be seen that there is an obvious difference in the fluorescence signal of the quartz glass well plate before and after modification of the fluorescent artificial antibody, which indicates that the artificial antibody can be modified onto the quartz glass well plate by the above method. 4. Stability of the quartz glass plate modified with fluorescent artificial antibodies
[0034] The stability of the modified nanoparticles was tested on different glass well plates. Figure 4 It can be seen that after the fluorescent artificial antibodies were modified in multiple wells, the RSD of the fluorescence signal was 4.65%, which indicates that the modification of artificial antibodies in the glass well plate has good repeatability and stability. Example 3: Performance of a kit for detecting the cardiovascular disease marker NT-proBNP 1. Detection Limit
[0035] The synthesized artificial antibody I was modified into a glass well plate according to the above method, and the concentration of NT-proBNP in serum was set to 0.1, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 10, 25, 50, 100, 200, 300, 400, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 40000 pg / mL, and 200 μL of serum samples were incubated for 6 min and washed three times with deionized water; then fluorescent artificial antibody II (0.1 mg / mL) was added and incubated for 6 min, washed three times with deionized water, and its absorbance at 520 nm was tested.
[0036] The change of fluorescence intensity with the change of NT-proBNP concentration was studied, and the analytical calibration was performed as a function of NT-proBNP concentration to evaluate the sensitivity of the detection method. A NT-proBNP calibration curve with good linearity (0.1 pg / mL-8,000 pg / mL) was obtained. The linear regression equation obtained by fitting was Y = 20.764 C (pg / mL) + 1576.6, and the correlation coefficient R 2 = 0.9965, e.g. Figure 5 As shown in the upper left, the LOD of the kit was calculated to be 2.52 pg / mL (S / N = 3) using the formula of 3Sb / m. Sb represents the standard deviation of the blank measurement (n = 10), and m represents the slope of the calibration curve. 2. Relative standard deviation (RSD) of artificial antibodies from the same batch
[0037] The artificial antibody I synthesized from the same batch was modified into a glass well plate according to the above method. The NT-proBNP concentration in the serum sample was set to 100 pg / ml. 200 μL of serum sample was added to the glass well plate (10 wells), incubated for 6 min, and then washed three times with deionized water. Then, the fluorescent artificial antibody II synthesized from the same batch (0.1 mg / mL) was added to each well and incubated for 6 min. The wells were washed three times with deionized water and their absorbance at 520 nm was tested. Figure 5 As can be seen from the upper right, the RSD of the same concentration of NT-proBNP serum samples detected based on artificial antibodies synthesized from the same batch is 2.73%. 3. Relative standard deviation (RSD) of different batches of artificial antibodies
[0038] Ten batches of artificial antibody I were synthesized and modified into glass well plates. The NT-proBNP concentration in serum samples was set to 100 pg / ml. 200 μL of serum samples were added to the glass well plates. After incubation for 6 min, the plates were washed three times with deionized water. Then, 100 μL of 10 batches of synthesized fluorescent artificial antibody II (0.1 mg / mL) was added to each well and incubated for 6 min. The plates were washed three times with deionized water and their absorbance at 520 nm was tested.
[0039] from Figure 5 As can be seen from the lower left, the RSD of 10 groups of artificial antibodies synthesized from different batches for detecting the same concentration of NT-proBNP serum samples is 2.17%, indicating that this method has good reproducibility. 4. Recovery rate
[0040] To evaluate the recovery of this method, NT-proBNP at concentrations of 50, 100, and 500 pg / mL were added to human serum samples of the same concentration of NT-proBNP. The RSD of 96.5~99.5% was in the range of 2.14~4.53%. The recovery was calculated as follows:
[0041] A: Determine the concentration of the substance to be tested in the sample; B: Add a certain amount of substance to be tested (the theoretical concentration of the substance to be tested is C).
[0042] Table 1 Recovery rate of NT-proBNP at a concentration of 50 pg / mL (C=50) 1 2 3 4 5 A 53.9587748 54.00693508 46.15680986 52.4658062 51.8397226 B 103.2748989 102.3116933 96.38797919 99.90367945 100.9150453 Table 2 Recovery rate of NT-proBNP at a concentration of 100 pg / mL (C=100) 1 2 3 4 5 A 105.6347525 99.03679445 106.3089963 105.8273936 99.75919861 B 201.2329031 200.7994606 198.4877673 198.5359276 200.1252167 Table 3 Recovery rate of NT-proBNP at a concentration of 500 pg / mL (C=500) 1 2 3 4 5 A 500.8379888 508.0620304 505.9911385 493.5657869 501.1751108 B 999.0560586 990.1464072 1009.314198 1003.968407 994.8661144 5. Detection results of actual serum samples
[0043] 200 μL of serum sample was added to the glass plate modified with artificial antibody I, incubated for 6 min, washed three times with deionized water, and then 100 μL of fluorescent artificial antibody II (0.1 mg / mL) was added to each well for 6 min, washed three times with deionized water, and its absorbance at 520 nm was tested. The kit was used to detect the concentration of NT-proBNP in the actual blood samples of 150 patients and compared with the test results of the hospital. Figure 5 As can be seen in the lower right corner, the test results of the kit are close to those of the hospital, and the RSD of the test is in the range of 0.01 ~4.84%. Example 4: Performance of a kit for detecting the cardiovascular disease marker cTnT 1. Detection Limit
[0044] The synthesized artificial antibody I was modified into a glass well plate according to the above method, and the cTnT concentration in serum was set to 1, 2, 4, 6, 8, 10, 15, 20, 25, 30, 40, 50, 75, 100, 500, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 20000, 40000 pg / mL. After incubation time of 200 μL of serum samples at each concentration for 6 min, the samples were washed three times with deionized water. Then, fluorescent artificial antibody II (0.1 mg / mL) was added and incubated for 6 min, the samples were washed three times with deionized water, and their absorbance at 520 nm was tested.
[0045] The change of fluorescence intensity with the change of cTnT concentration was studied, and the analytical calibration was performed as a function of cTnT concentration to evaluate the sensitivity of the detection method. A cTnT calibration curve with good linearity (1 pg / mL~8,000pg / mL) was obtained. The linear regression equation obtained by fitting was Y = 4.3901 C (pg / mL) + 319.88, and the correlation coefficient R 2 =0.9986, e.g. Figure 6 As shown in the upper left. The LOD of the kit was calculated using the formula of 3Sb / m to be 11.91 pg / mL (S / N = 3). Sb represents the standard deviation of the blank measurement (n = 10), and m represents the slope of the calibration curve. 2. Relative standard deviation (RSD) of artificial antibodies in the same batch
[0046] The artificial antibody I synthesized from the same batch was modified into a glass plate according to the above method. The cTnT concentration in the serum sample was set to 100 pg / ml. 200 μL of serum sample was added to the glass plate (10 wells) and incubated for 6 min. The wells were washed three times with deionized water. Then, fluorescent artificial antibody II (0.1 mg / mL) was added to each well and incubated for 6 min. The wells were washed three times with deionized water and their absorbance at 520 nm was tested. Figure 6 As can be seen from the upper right, the RSD of the cTnT serum samples with the same concentration detected by artificial antibodies synthesized from the same batch is 2.37%. 3. Relative standard deviation (RSD) of different batches of artificial antibodies
[0047] Ten batches of artificial antibody I were synthesized and modified into glass well plates. The cTnT concentration in serum samples was set to 100 pg / ml. 200 μL of serum samples were added to the glass well plates. After incubation for 6 min, the plates were washed three times with deionized water. Then, 100 μL of fluorescent artificial antibody II (0.1 mg / mL) synthesized in 10 batches was added to each well and incubated for 6 min. The plates were washed three times with deionized water and their absorbance at 520 nm was tested.
[0048] from Figure 6 As can be seen from the lower left, the RSD of 10 groups of artificial antibodies synthesized from different batches for detecting cTnT serum samples with the same concentration is 1.24%, indicating that this method has good reproducibility. 4. Recovery rate
[0049] To evaluate the recovery of this method, cTnT at concentrations of 50, 100, and 500 pg / mL were added to human serum cTnT samples of the same concentration. The RSD of 93.7-96.5% was in the range of 2.72-4.01%. The recovery was calculated as follows:
[0050] A: Determine the concentration of the substance to be tested in the sample; B: Add a certain amount of substance to be tested (the theoretical concentration of the substance to be tested is C) and measure the concentration.
[0051] Table 4 Recovery rate of cTnT at a concentration of 50 pg / mL (C=50) 1 2 3 4 5 A 47.6344502 54.4680076 53.5568666 54.6957928 55.1513633 B 95.0137810 104.5807613 101.1639826 101.3917678 102.7584793 Table 5 Recovery rate of cTnT at a concentration of 100 pg / mL (C=100) 1 2 3 4 5 A 112.0976743 98.8861302 105.0363317 113.2366005 113.0088153 B 204.5784834 198.8838523 196.6059999 207.3119063 203.4395572 Table 6 Recovery rate of cTnT at a concentration of 500 pg / mL (C=500) 1 2 3 4 5 A 509.12735473 507.98842851 512.99970388 515.04977108 500.92708594 B 1005.24361632 972.67032642 995.90442131 1011.62160315 972.21475593 5. Detection results of actual serum samples
[0052] 200 μL of serum sample was added to the glass plate modified with artificial antibody I, incubated for 6 min, washed three times with deionized water, and then 100 μL of fluorescent artificial antibody II (0.1 mg / mL) was added to each well for 6 min, washed three times with deionized water, and its absorbance at 520 nm was tested. The kit was used to detect the concentration of cTnT in the actual blood samples of 150 patients and compared with the test results of the hospital. Figure 6 As can be seen in the lower right corner, the test results of the kit are close to those of the hospital, and the RSD of the test is in the range of 0.16~4.96%. Example 5: Preparation of immunomagnetic bead kit
[0053] (1) Soak 1 mg of phenylmethylsulfonyl magnetic particles in 2 mL of 0.1 M boric acid + 3 M ammonium sulfate solution (pH 9.50) to obtain magnetic particles with amino functional groups; (2) Prepare 5 mg / mL pentapeptide (Cys-Glu-Cys-Gly-Cys) solution and 1 mg / mL sulfonic acid-SMCC solution in 0.01 M PBS (pH 7.2-7.4). Add the magnetic particles with amino functional groups obtained in step (1) to the sulfonic acid-SMCC solution and react at room temperature for 30 min. Rinse with deionized water 2-3 times. Then add to the peptide solution and react at room temperature for 30 min. Rinse with deionized water 2-3 times. Add to the sulfonic acid-SMCC solution and react at room temperature for 30 min. Rinse with deionized water 2-3 times.
[0054] (3) Finally, the magnetic particles in step (2) were added to the artificial antibody I solution prepared in Example 1 (concentration 0.1 mg / mL, diluted with PBS, pH = 6.8), and reacted in a shaker at 37 ° C for 20 h. This step can be repeated 3-5 times until the artificial antibody coupling is saturated.
[0055] In order to verify whether this method is effective in detecting the concentration of NT-proBNP, a cardiovascular disease marker, we constructed the kit and tested its detection performance. Figure 7 It can be seen that there is a linear relationship between different sample numbers and the detected fluorescence signals.
Claims
1. A sandwich kit for detecting cardiovascular disease markers, characterized in that: The kit consists of artificial antibody II and artificial antibody I modified on a carrier material.
2. The sandwich kit for detecting cardiovascular disease markers according to claim 1, characterized in that: The carrier material is amino-modified glass or a magnetic material with amino functional groups.
3. The sandwich kit for detecting cardiovascular disease markers according to claim 2, characterized in that: The modification method of the amino-modified glass is as follows: treating the glass with acid, alkali and ethanol solution in sequence to activate the hydroxyl groups; then adding 1-20wt% APTMS ethanol solution, 25-40 o C for 6-24h, and finally rinse with ultrapure water.
4. The sandwich kit for detecting cardiovascular disease markers according to claim 3, characterized in that: The acid treatment uses a 0.5-5 M hydrochloric acid solution, the alkali treatment uses a 0.5-5 M sodium hydroxide solution, and the ethanol solution is an ethanol aqueous solution with a volume content of 50-95%.
5. The sandwich kit for detecting cardiovascular disease markers according to claim 1, characterized in that: The cardiovascular disease marker is NT-proBNP, BNP, Myo, CK-MB, cTnT or cTnI.
6. The sandwich kit for detecting cardiovascular disease markers according to claim 1, characterized in that: The preparation method of the artificial antibody I is: preparing a mixed monomer solution with a concentration of 13-65 mM, wherein the mixed monomer is a molar ratio of 45-98:5-45:5-45:1-10:1-5 N -Isopropyl acrylamide, N -tert-Butyl acrylamide, N -phenylacrylamide, N -(3-aminopropyl)methacrylamide and N,N' -methylenebisacrylamide, then sodium dodecyl sulfate is added in an amount of 0.02-0.2 mg / mL, nitrogen is passed through the solution by ultrasound for 5-30 min to remove oxygen, and then ammonium persulfate is added to initiate the polymerization reaction in an amount of 0.6-1.2 mg / mL. The polymer nanoparticles synthesized are artificial antibody I.
7. The sandwich kit for detecting cardiovascular disease markers according to claim 1, characterized in that: The preparation method of the artificial antibody II is as follows: preparing a mixed monomer solution with a concentration of 13-65 mM, wherein the mixed monomers are N-isopropylacrylamide, N-tert-butylacrylamide, N-phenylacrylamide, acrylic acid and N,N'-methylenebisacrylamide in a molar ratio of 45-98:5-45:5-10:1-10:1-5, then adding sodium dodecyl sulfate in an amount of 0.02-0.2 mg / mL, ultrasonically passing nitrogen gas for 5-30 min to remove oxygen in the solution, then adding fluorescein in an amount of 0.04-0.1 mg / mL, and finally adding ammonium persulfate to initiate a polymerization reaction, wherein the amount of ammonium persulfate added is 0.6-1.2 mg / mL, and synthesizing fluorescently labeled polymer nanoparticles, namely artificial antibody II.
8. The sandwich kit for detecting cardiovascular disease markers according to claim 1, characterized in that: The method for modifying the artificial antibody I on the carrier material is as follows: first, the carrier material is added to a 0.5-2 mg / mL sulfo-SMCC solution for reaction at room temperature for 20-50 min, and then the carrier material is taken out and rinsed with deionized water; then, the carrier material is added to a 1-5 mg / mL Cys-Glu-Cys-Gly-Cys pentapeptide solution for reaction at room temperature for 20-50 min, and then the carrier material is taken out and rinsed with deionized water; then, the carrier material is added to a 0.5-2 mg / mL sulfo-SMCC solution for reaction at room temperature for 20-50 min, and then the carrier material is taken out and rinsed with deionized water; finally, a phosphate buffer solution of artificial antibody I with a concentration of 0.05-1 mg / mL is added, and then the carrier material is rinsed with deionized water for 35-50 min. o C for 10-30h and then washed with ultrapure water.
9. A method for using the sandwich kit for detecting cardiovascular disease markers prepared according to the method of any one of claims 1 to 8, characterized in that: The specific operation of the method of use is: adding the test sample to the carrier material modified with artificial antibody I for adsorption reaction at room temperature for 5-10 minutes, and washing with deionized water; then adding artificial antibody II solution, reacting at room temperature for 5-10 minutes, and washing with deionized water; Finally, the content of cardiovascular disease markers in the test samples was quantitatively determined by detecting the fluorescence signal.
